1. FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
   Sang Hee Cho et al, 2017, Cancer Res Treat CrossRef
2. Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells
   Hwa Jun Cha et al, 2017 CrossRef
3. The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics
   Jason N. Rosenbaum et al, 2017, The American Journal of Pathology CrossRef
4. FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
   Lukasz Turczyk et al, 2017, Neoplasia CrossRef
5. bFGF in tumor tissue independently prognosticates disease outcome of a natural course of invasive breast cancer
   Nataša Todorović-Raković et al, 2017, CBM CrossRef
6. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
   Bernhard Englinger et al, 2017, J Exp Clin Cancer Res CrossRef
7. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
   Tomohiro Nishina et al, 2017, Invest New Drugs CrossRef
8. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
   Narayan Shivapurkar et al, 2017, Clin Trans Med CrossRef
9. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
   K P Papadopoulos et al, 2017, Br J Cancer CrossRef
10. The integration of genomics testing and functional proteomics in the era of personalized medicine
    Masaru Katoh, 2017, Expert Review of Proteomics CrossRef
11. Myeloid/lymphoid neoplasms with FGFR1 rearrangement
    Paolo Strati et al, 2017, Leukemia & Lymphoma CrossRef
12. Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy
    Ana Cavaco et al, 2017, IJMS CrossRef
13. Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity
    Samantha Louise Cooper et al, 2017, Toxicology CrossRef
14. Assessment of FGFR1 Overexpression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening
    Penghui HU et al, 2017, Human Gene Therapy Methods CrossRef
15. Splice variants of porcine PPHLN1 encoding periphilin-1
    Knud Larsen et al, 2017, Gene Reports CrossRef
16. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer
    Katarzyna Starska et al, 2018, Cell Oncol. CrossRef
17. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
    Masaru Katoh, 2017, Int J Oncol CrossRef
18. Soluble interleukin-2 receptor as a factor associated with angiogenesis in gastric cancer
    Wen-Feng Yan et al, 2017 CrossRef
19. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis
    S J Welsh et al, 2018, Leukemia CrossRef
20. Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
    Yikai Wang et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
21. QSAR and Structure-Based Docking Studies of Aryl Pyrido[2,3-d]pyrimidin-7(8H)-ones
    Jyoti Durgapal et al, 2018 CrossRef
22. SNCA , a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis
    Yong-Xiao Li et al, 2018, Cancer Sci CrossRef
23. Therapeutics Targeting FGF Signaling Network in Human Diseases
    Masaru Katoh, 2016, Trends in Pharmacological Sciences CrossRef
24. Prognostic importance of FGF2 and FGFR1 expression for patients affected by ameloblastoma
    Felipe Paiva Fonseca et al, 2018, J Oral Pathol Med CrossRef
25. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma
    Ayano Kabashima et al, 2018, Journal of Hepatology CrossRef
26. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms
    Stephan Bartels et al, 2018, Virchows Arch CrossRef
27. Tumor microenvironment – Unknown niche with powerful therapeutic potential
    Tomasz Kolenda et al, 2018, Reports of Practical Oncology & Radiotherapy CrossRef
28. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4
    You-Lu Pan et al, 2018, Molecules CrossRef
29. Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
    Manman Wei et al, 2018, European Journal of Medicinal Chemistry CrossRef
30. Papillomavirus E2 protein is regulated by specific fibroblast growth factor receptors
    Marsha DeSmet et al, 2018, Virology CrossRef
31. Klotho negatively regulated aerobic glycolysis in colorectal cancer via ERK/HIF1α axis
    Qingguo Li et al, 2018, Cell Commun Signal CrossRef
32. Future applications of FGF/FGFR inhibitors in cancer
    Gaia Cristina Ghedini et al, 2018, Expert Review of Anticancer Therapy CrossRef
33. Inferring Novel Tumor Suppressor Genes with a Protein-Protein Interaction Network and Network Diffusion Algorithms
    Lei Chen et al, 2018, Molecular Therapy - Methods & Clinical Development CrossRef
34. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
    Navid Sobhani et al, 2018, Cells CrossRef
35. Recent developments and advances of FGFR as a potential target in cancer
    Wen-Jun Xue et al, 2018, Future Medicinal Chemistry CrossRef
36. Novel pyrrole derivatives bearing sulfonamide groups: Synthesis in vitro cytotoxicity evaluation, molecular docking and DFT study
    Masoumeh Bavadi et al, 2017, Journal of Molecular Structure CrossRef
37. Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis
    D. S. Mikhaylenko et al, 2018, Biochemistry Moscow CrossRef
38. Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway
    Navid Koleini et al, 2018, Cell Tissue Res CrossRef
39. Making way for suppressing the FGF19/FGFR4 axis in cancer
    Nestor Prieto-Dominguez et al, 2018, Future Medicinal Chemistry CrossRef
40. Fibroblast growth factor receptors as treatment targets in clinical oncology
    Masaru Katoh, 2018, Nat Rev Clin Oncol CrossRef
41. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors
    Jing Cui et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
42. Hepatic gene body hypermethylation is a shared epigenetic signature of murine longevity
    Oliver Hahn et al, 2018, PLoS Genet CrossRef
43. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
    Brendan Farrell et al, 2018, Biochm. Soc. Trans. CrossRef
44. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
    Bao T. Le et al, 2019, Molecular Therapy - Nucleic Acids CrossRef
45. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
    Maria Kalyukina et al, 2019, ChemMedChem CrossRef
46. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
    Charlotte M. Huijts et al, 2019, Cancer Immunol Immunother CrossRef
47. Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma
    H.M. Surowy et al, 2019, Br J Dermatol CrossRef
48. Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2: Potential Cancer Therapeutic Agent
    Keng-Chang Tsai et al, 2019, ACS Omega CrossRef
49. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
    Burcu Dogan-Topal et al, 2019, Journal of Chromatography B CrossRef
50. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    R Condorelli et al, 2019, Ann Oncol CrossRef
51. null
    Scott A. Hundahl et al, 2006 CrossRef
52. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models
    Sylvia Grünewald et al, 2019, Int. J. Cancer CrossRef
53. GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells Toward Breast Tumor Progression
    Maria Francesca Santolla et al, 2019, Cells CrossRef
54. Silencing fibroblast growth factor 7 inhibits krypton laser‐induced choroidal neovascularization in a rat model
    Chao Zhang et al, 2019, J Cell Biochem CrossRef
55. The evolving genomic landscape of urothelial carcinoma
    Alexander P. Glaser et al, 2017, Nat Rev Urol CrossRef
56. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.
    Masaru Katoh, 2019, Clin Sci (Lond) CrossRef
57. MiR‐16‐1‐3p and miR‐16‐2‐3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma
    Vadim V. Maximov et al, 2019, Int. J. Cancer CrossRef
58. Menstrual and Reproductive Factors, Exogenous Hormone Use, and Gastric Cancer Risk in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition
    Eric J. Duell et al, 2010 CrossRef
59. MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing FGFR1 in gastric cancer
    Junxia Gu et al, 2019, Biosci. Rep. CrossRef
60. Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1
    Elizabeth A McNiel et al, 2017, Sig Transduct Target Ther CrossRef
61. Critical role of the fibroblast growth factor signalling pathway in Ewing's sarcoma octamer‐binding transcription factor 4‐mediated cell proliferation and tumorigenesis
    Junghoon Kim et al, 2019, FEBS J CrossRef
62. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
    Shuyan Dai et al, 2019, Cells CrossRef
63. Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis
    Liduan Zheng et al, 2012, J Cancer Res Clin Oncol CrossRef
64. Fibroblast Growth Factor Receptor Signaling in Skin Cancers
    null Czyz, 2019, Cells CrossRef
65. MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells
    Patrice Cagle et al, 2019, Sci Rep CrossRef
66. Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer
    Bartosz Adam Frycz et al, 2013, Biomedicine & Pharmacotherapy CrossRef
67. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
    Frank Hilberg et al, 2018, J Pharmacol Exp Ther CrossRef
68. Genetics of breast cancer bone metastasis: a sequential multistep pattern
    Hassan Fazilaty et al, 2014, Clin Exp Metastasis CrossRef
69. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
    Martin Schuler et al, 2019, The Lancet Oncology CrossRef
70. A new screening tool for FGFR inhibitor treatment?
    Aung Naing, 2019, The Lancet Oncology CrossRef
71. Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
    Yi-Han Chiu et al, 2019, Journal of Oncology CrossRef
72. Gastric cancer management: Kinases as a target therapy
    Batoul Farran et al, 2017, Clin Exp Pharmacol Physiol CrossRef
73. Genetics of Pheochromocytomas and Paragangliomas
    Rodrigo Almeida Toledo, 2017, Endocrinology and Metabolism Clinics of North America CrossRef
74. A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael Michael et al, 2017, Targ Oncol CrossRef
75. Targeted and novel therapy in advanced gastric cancer
    Julie H. Selim et al, 2019, Exp Hematol Oncol CrossRef
76. null
    Michael A. Schumacher et al, 2018 CrossRef
77. Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer
    null Holzmann et al, 2019, Cells CrossRef
78. Targeting FGFR in bladder cancer: ready for clinical practice?
    Stijn De Keukeleire et al, 2020, Acta Clin Belg CrossRef
79. Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype
    Kelsie E. Oatmen et al, 2019, Nat Rev Cardiol CrossRef
80. Fibroblast growth factor receptor inhibitors: patent review (2015–2019)
    Giuseppe Marseglia et al, 2019, Expert Opinion on Therapeutic Patents CrossRef
81. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
    Robert Roskoski, 2019, Pharmacological Research CrossRef
82. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
    Chiara Casadei et al, 2019, Ther Adv Med Oncol CrossRef
83. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
    Fangda Li et al, 2019, Cytokine & Growth Factor Reviews CrossRef
84. Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma
    Ming-Dow Tsay et al, 2019, IJERPH CrossRef
85. Cancer immunotherapy: Pros, cons and beyond.
    Shuzhen Tan et al, 2020, Biomed Pharmacother CrossRef
86. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
    Tatjana Seitz et al, 2020, Sci Rep CrossRef
87. The future of bladder cancer therapy: optimizing the inhibition of the fibroblast growth factor receptor
    Rafael Morales-Barrera et al, 2020, Cancer Treatment Reviews CrossRef
88. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
    Sobhani Navid et al, 2020, IJMS CrossRef
89. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
    Sara Massironi et al, 2020, Cells CrossRef
90. Trefoil factor family (TFF) peptides and cancer progression
    Shahin Emami et al, 2004, Peptides CrossRef
91. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.
    Jian Ming Xu et al, 2017, Oncotarget CrossRef
92. Stable Fibroblast Growth Factor 2 Dimers with High Pro-Survival and Mitogenic Potential
    Daria Nawrocka et al, 2020, IJMS CrossRef
93. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors
    Qian Qin et al, 2020, Expert Review of Anticancer Therapy CrossRef
94. Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
    Elizabeth K. Lee et al, 2020, JCO Precision Oncology CrossRef
95. Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP‑1 cells
    Yuri Miyazoe et al, 2020, biom rep CrossRef
96. Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance
    Lingling Ou et al, 2020, Mol Med Report CrossRef
97. Precision medicine for human cancers with Notch signaling dysregulation (Review)
    Masuko Katoh et al, 2019, Int J Mol Med CrossRef
98. Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
    Jing Wang et al, 2020, Ther Adv Med Oncol CrossRef
99. Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects
    Hongjie Qian et al, 2020, Clinical Therapeutics CrossRef
100. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
     Ramona Erber et al, 2020, Breast Cancer Res Treat CrossRef
101. Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma
     Denggang Fu et al, 2020, Front. Genet. CrossRef
102. A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates
     Ping Yu et al, 2020, Toxicology and Applied Pharmacology CrossRef
103. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
     Jianming Xu et al, 2020, Lancet Oncol CrossRef
104. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma
     Saori Miyajima et al, 2020, Clin J Gastroenterol CrossRef
105. Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions
     Mathijs Scholtes et al, 2020, Applied Sciences CrossRef
106. MiR-497 promotes microglia activation and proinflammatory cytokines production in chronic unpredictable stress-induced depression via targeting FGF2
     Xiaoyan Zhai et al, 2020, Journal of Chemical Neuroanatomy CrossRef
107. Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis
     Jesse Hirner et al, 2020, JAMA Dermatol CrossRef
108. Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling.
     Junghwa Choi et al, 2020, Int J Mol Sci CrossRef
109. A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer
     Ke Xu et al, 2020 CrossRef
110. Epithelial Splicing Regulatory Protein (ESPR1) Expression in an Unfavorable Prognostic Factor in Prostate Cancer Patients
     Hyung Ho Lee et al, 2020, Front. Oncol. CrossRef
111. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
     Mario E. Lacouture et al, 2020, The Oncol CrossRef
112. Blockade of Fgfr1 with PD166866 Protects Cartilage from the Catabolic Effects Induced by Interleukin-1β: A Genome-Wide Expression Profiles Analysis
     Lingxian Yi et al, 2020, CARTILAGE CrossRef
113. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
     T. E. Kähkönen et al, 2020, Cell Oncol. CrossRef
114. Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: Report of three cases
     G. Bauters et al, 2020, Journal Français d'Ophtalmologie CrossRef
115. Discovery and Optimization of Novel Pyrazole-Benzimidazole CPL304110, as a Potent and Selective Inhibitor of Fibroblast Growth Factor Receptors FGFR (1-3)
     Abdellah Yamani et al, 2020, European Journal of Medicinal Chemistry CrossRef
116. CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer
     Xiaoguang Qi et al, 2020, Technol Cancer Res Treat CrossRef
117. Compounds from Natural Sources as Protein Kinase Inhibitors
     Andrea Baier et al, 2020, Biomolecules CrossRef
118. Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome
     Peipei Wang et al, 2020, BioMed Research International CrossRef
119. Clinical Characteristics and Spermatogenesis in Patients with Congenital Hypogonadotropic Hypogonadism Caused by FGFR1 Mutations
     Shuying Li et al, 2020, International Journal of Endocrinology CrossRef
120. A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2
     Yibo Zhang et al, 2020, MedComm CrossRef
121. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
     Sangeetha Palakurthi et al, 2019, Cancer Immunol Res CrossRef
122. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
     Timothy P.S. Perera et al, 2017, Mol Cancer Ther CrossRef
123. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
     Martin H Voss et al, 2019, Clin Cancer Res CrossRef
124. Promoting Effect of Basic Fibroblast Growth Factor in Synovial Mesenchymal Stem Cell-Based Cartilage Regeneration
     Gensuke Okamura et al, 2020, IJMS CrossRef
125. The diagnostic and clinicopathological value of Trefoil Factor 3 in patients with gastric cancer: a systematic review and meta-analysis
     Chen-Xing Zhang et al, 2021, Biomarkers CrossRef
126. Recent advances of dual FGFR inhibitors as a novel therapy for cancer
     Qi Liang et al, 2021, European Journal of Medicinal Chemistry CrossRef
127. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma
     Ling Zhao et al, 2021, Cancer Cell Int CrossRef
128. FGFR-TKI resistance in cancer: current status and perspectives
     Sitong Yue et al, 2021, J Hematol Oncol CrossRef
129. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
     Silvana Mouron et al, 2021, Breast Cancer Res CrossRef
130. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
     Manali Tilak et al, 2021, IJMS CrossRef
131. The Effects of Naringenin on miRNA-mRNA Profiles in HepaRG Cells
     Weiyang Fan et al, 2021, IJMS CrossRef
132. Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
     Guihong Liu et al, 2021, Cell Prolif CrossRef
133. Surufatinib: First Approval.
     Yahiya Y Syed, 2021, Drugs CrossRef
134. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy
     Thomas Neill et al, 2021, Matrix Biology CrossRef
135. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
     Maria-Magdalena Georgescu et al, 2021, acta neuropathol commun CrossRef
136. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets
     Haijun Wang et al, 2021, Front. Pharmacol. CrossRef
137. Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer
     Yanan Liu et al, 2021, Front. Pharmacol. CrossRef
138. Fibroblasts as immune regulators in infection, inflammation and cancer
     Sarah Davidson et al, 2021, Nat Rev Immunol CrossRef
139. Activated ERK Signaling Is One of the Major Hub Signals Related to the Acquisition of Radiotherapy-Resistant MDA-MB-231 Breast Cancer Cells.
     Gon-sup Kim, 0 CrossRef
140. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
     Laura Pacini et al, 2021, Cells CrossRef
141. δ-Catenin Participates in EGF/AKT/p21Waf Signaling and Induces Prostate Cancer Cell Proliferation and Invasion
     Yingjie Shen et al, 2021, IJMS CrossRef
142. Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes
     Ranjithkumar Rajendran et al, 2021, Cells CrossRef
143. Clinical Application of Cytokines in Cancer Immunotherapy
     Yi Qiu et al, 2021, DDDT CrossRef
144. Deciphering the whale's secrets to have a long life
     Francisco Alejandro Lagunas-Rangel, 2021, Experimental Gerontology CrossRef
145. Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
     Alexandru Nita et al, 2021, Cells CrossRef
146. GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
     Kaili Jiang et al, 2021, Cancer Med CrossRef
147. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
     Anuhya Kommalapati et al, 2021, Cancers CrossRef
148. Identification of key classification features of early cervical squamous cell carcinoma
     Xiaoxi Wang et al, 2021, Computational Biology and Chemistry CrossRef
149. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer
     Keiko Minashi et al, 2021 CrossRef
150. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
     Gentry King et al, 2021, Curr Oncol Rep CrossRef
151. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
     Ikuko Takeda Nakamura et al, 2021, npj Precis. Onc. CrossRef
152. Development and Characterization of a Novel Peptide—Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors
     Yayu Wang et al, 2021, Biomedicines CrossRef
153. The protein-protein interaction network of intestinal gastric cancer patients reveals hub proteins with potential prognostic value
     Everton Cruz Santos et al, 2021, CBM CrossRef
154. DARK AND BRIGHT SIDE OF TARGETING THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN THE LIVER
     Raffaella Maria Gadaleta et al, 2021, Journal of Hepatology CrossRef
155. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance
     Fariba Dehghanian et al, 2021, Sci Rep CrossRef
156. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
     Richard S. Finn et al, 2021, Clin Cancer Res CrossRef
157. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment
     Hye Won Lee et al, 2021, IJMS CrossRef
158. Identifying Lung Cancer Cell Markers with Machine Learning Methods and Single-Cell RNA-Seq Data
     Guo-Hua Huang et al, 2021, Life CrossRef
159. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma
     Ye Wu et al, 2021, Molecular Therapy CrossRef
160. Melatonin Suppresses Oral Squamous Cell Carcinomas Migration and Invasion through Blocking FGF19/FGFR 4 Signaling Pathway
     Leilei Wang et al, 2021, IJMS CrossRef
161. Comprehending Fibroblast Growth Factor Receptor Like 1: Oncogene or Tumor suppressor?
     null Aprajita et al, 2021, Cancer Treatment and Research Communications CrossRef
162. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
     Yanyang Liu et al, 2021, Front. Oncol. CrossRef
163. Safflower Polysaccharide Inhibits AOM/DSS-Induced Mice Colorectal Cancer Through the Regulation of Macrophage Polarization
     Qun Wang et al, 2021, Front. Pharmacol. CrossRef
164. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
     James Yu et al, 2021, OTT CrossRef
165. Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma
     Natthaphong Nimitrungtawee et al, 2021, Cancer Med CrossRef
166. Glioma cell-derived FGF20 suppresses macrophage function by activating β-catenin
     Xue Cai et al, 2021, Cellular Signalling CrossRef
167. FGF10/FGF17 as prognostic and drug response markers in acute myeloid leukemia
     Yanying Ling et al, 2022, Current Research in Translational Medicine CrossRef
168. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
     Liping Hu et al, 2021, European Journal of Medicinal Chemistry CrossRef
169. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
     Lingfeng Chen et al, 2021, J Exp Clin Cancer Res CrossRef
170. The Upregulation of PLXDC2 Correlates with Immune Microenvironment Characteristics and Predicts Prognosis in Gastric Cancer
     Yang Li et al, 2021, Disease Markers CrossRef
171. Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
     Naomi Suzuki et al, 2020, Case Rep Gastroenterol CrossRef
172. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential
     Claudia Ceci et al, 2022, Pharmacology & Therapeutics CrossRef
173. Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signaling pathway in non-small-cell lung cancer
     Lehe Yang et al, 2022, Phytomedicine CrossRef
174. Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
     Huey-Jen Lin et al, 2022, Cancers CrossRef
175. Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression
     Lan Yu et al, 2022, Cancers CrossRef
176. Kinases and therapeutics in pathogen mediated gastric cancer
     Charu Sonkar et al, 2022, Mol Biol Rep CrossRef
177. Metastatic Immune-Related Genes for Affecting Prognosis and Immune Response in Renal Clear Cell Carcinoma
     Si Sun et al, 2022, Front. Mol. Biosci. CrossRef
178. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
     Zeynep B. Zengin et al, 2022, Urologic Oncology: Seminars and Original Investigations CrossRef
179. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
     Sakti Chakrabarti et al, 2022, Expert Opin Drug Metab Toxicol CrossRef
180. Pindborg Tumor—An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC
     Anna Herden et al, 2022, Diagnostics CrossRef
181. Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass
     Jiun-Yu Guo et al, 2022, Nutrients CrossRef
182. New developments in the biology of fibroblast growth factors
     David M. Ornitz et al, 2022, WIREs Mechanisms of Disease CrossRef
183. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications
     Kengo Nakahata et al, 2022 CrossRef
184. Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents
     Jaya Kala et al, 2021, Advances in Chronic Kidney Disease CrossRef
185. Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer
     Chiara Francavilla et al, 2022, Open Biol. CrossRef
186. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
     Robert J. Motzer et al, 2022, Expert Review of Anticancer Therapy CrossRef
187. null
     Mohini Singh et al, 2022 CrossRef
188. Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
     Ajaz Ahmad Waza et al, 2021, CCDT CrossRef
189. In search of inhibitors of anti-cancer drug target Fibroblast Growth Factor Receptors: insights from virtual screening, molecular docking, and molecular dynamics study
     A.M.U.B Mahfuz et al, 2022, Arabian Journal of Chemistry CrossRef
190. Correlation between amino acid metabolism and self-renewal of cancer stem cells: Perspectives in cancer therapy
     Qi Zhang et al, 2022, WJSC CrossRef
191. FGFR1 is a potential therapeutic target in neuroblastoma
     Flora Cimmino et al, 2022, Cancer Cell Int CrossRef
192. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
     Mariangela Tamburello et al, 2022, Endocrine CrossRef
193. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment
     Chunting Zeng et al, 2022, BMC Cancer CrossRef
194. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.
     Hui Liu et al, 2018, Cancer Discov CrossRef
195. Age‐related decrease in responsiveness of CD271 ‐positive skin stem cells to growth factors
     Hirohiko Akamatsu et al, 2022, Experimental Dermatology CrossRef
196. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer
     Xiuli Wu et al, 2022, Bioorganic Chemistry CrossRef
197. Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D Crystal Structure of Infigratinib - A Drug Used in the Treatment of Cholangiocarcinomas
     Koushik Sarker et al, 2022, LDDD CrossRef
198. Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
     Menglong Zhang et al, 2022, Disease Markers CrossRef
199. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
     Yun Liu et al, 2022, J Hematol Oncol CrossRef
200. Vitamin D Derivatives in Acute Myeloid Leukemia: The Matter of Selecting the Right Targets
     Ewa Marcinkowska, 2022, Nutrients CrossRef
201. Modeling Lung Carcinoids with Zebrafish Tumor Xenograft.
     Michele Caraglia, 0 CrossRef
202. Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
     Andliena Tahiri et al, 2022, Oncotarget CrossRef
203. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
     Qi Sun et al, 2022, Cell Death Dis CrossRef
204. Circ_SNX27 regulates hepatocellular carcinoma development via miR ‐637/ FGFR1 axis
     Hua Li et al, 2022, Environmental Toxicology CrossRef
205. Overexpressed fibroblast growth factor receptors increase 1,25-dihydroxyvitamin D-dependent differentiation of acute myeloid leukemia cells
     Aleksandra Marchwicka et al, 2022, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
206. Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
     Guanghui Gao et al, 2022, Intl Journal of Cancer CrossRef
207. Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer
     Chengcheng Yang et al, 2022, Front. Oncol. CrossRef
208. A robust Spearman correlation coefficient permutation test
     Han Yu et al, 2022, Communications in Statistics - Theory and Methods CrossRef
209. Cancer-Associated Fibroblasts: The Origin, Biological Characteristics and Role in Cancer—A Glance on Colorectal Cancer
     Charalampos Fotsitzoudis et al, 2022, Cancers CrossRef
210. A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to fluorouracil beneficial responses in gastric cancer
     Shaowei Dong et al, 2022, Front. Immunol. CrossRef
211. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
     David J Benjamin et al, 2022, Clin Med Insights Oncol CrossRef
212. AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy
     Yun Feng et al, 2022, ACAMC CrossRef
213. Variant Enrichment Analysis to Explore Pathways Disruption in a Necropsy Series of Asbestos-Exposed Shipyard Workers
     Sergio Crovella et al, 2022, IJMS CrossRef
214. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion
     Michael H. Storandt et al, 2022, Expert Review of Anticancer Therapy CrossRef
215. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors
     Hamidreza Zalpoor et al, 2022, Cell Commun Signal CrossRef
216. Fibroblast growth factor 2 is a druggable target against glioblastoma: A computational investigation
     Rabeea Siddique et al, 2022, Front. Chem. CrossRef
217. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
     Lei Pan et al, 2023, Front. Immunol. CrossRef
218. Angiogenesis-related gene signatures reveal the prognosis of cervical cancer based on single cell sequencing and co-expression network analysis
     Jiawen Kang et al, 2023, Front. Cell Dev. Biol. CrossRef
219. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
     Hui Zeng et al, 2023, Front. Immunol. CrossRef
220. Glycopolymers for Antibacterial and Antiviral Applications
     Ruoyao Mei et al, 2023, Molecules CrossRef
221. CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
     Haruto Nishida et al, 2023, PLoS ONE CrossRef
222. Basic Fibroblast Growth Factor Blockade Leads to Distinct Cellular Responses in Melanoma B16 Cells
     Zhiyong Wang et al, 2022, Dokl Biochem Biophys CrossRef
223. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy
     Xiu-Juan Liu et al, 2023, Bioorganic Chemistry CrossRef
224. Role of FGFR3 in Bladder Cancer: treatment landscape and future challenges
     Claudia Maria Ascione et al, 2023, Cancer Treatment Reviews CrossRef
225. Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement
     Somprakash Dhangar et al, 2023, Cancer Genetics CrossRef
226. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
     Ruiwen Ruan et al, 2023, Mol Cancer CrossRef
227. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
     Subhasmita Mahapatra et al, 2023, Journal of Biomolecular Structure and Dynamics CrossRef
228. Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
     Anqi Lin et al, 2023, JIR CrossRef
229. Expression and Purification of FGFR1-Fc Fusion Protein, and its Effects on Human Lung Squamous Carcinoma
     Lulu Zheng et al, 2022, SSRN Journal CrossRef
230. Important oncogenic and immunogenic roles of SPP1 and CSF1 in hepatocellular carcinoma
     Tianxin Xiang et al, 2023, Med Oncol CrossRef
231. Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma
     Lulu Zheng et al, 2023, Appl Biochem Biotechnol CrossRef
232. Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID
     J. Narayanan et al, 2023, Arch Microbiol CrossRef
233. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor
     Maroun Bou Zerdan et al, 2023, Mol Diagn Ther CrossRef
234. Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma
     Hajime Asada et al, 2023, Sci Rep CrossRef
235. Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment
     Song Liao et al, 2023, Front. Oncol. CrossRef
236. Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1
     Daria Nawrocka et al, 2023, IJMS CrossRef
237. Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer
     Yujie Lu et al, 2023, Front. Immunol. CrossRef
238. Identification of novel biomarkers and immune infiltration features of recurrent pregnancy loss by machine learning
     Yujia Luo et al, 2023, Sci Rep CrossRef
239. Comprehensive analysis of the role of a four-gene signature based on EMT in the prognosis, immunity, and treatment of lung squamous cell carcinoma
     Feng Li et al, 2023, Aging CrossRef
240. The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti‐inflammatory effects and remyelination in a model of multiple sclerosis
     Ranjithkumar Rajendran et al, 2023, British J Pharmacology CrossRef
241. Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells
     Yilin Xiong et al, 2023, Am J Cardiovasc Drugs CrossRef
242. Characterization of the folding and binding properties of the PTB domain of FRS2 with phosphorylated and unphosphorylated ligands
     Valeria Pennacchietti et al, 2023, Archives of Biochemistry and Biophysics CrossRef
243. The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study
     Jia-ying Chen et al, 2023, Ann Surg Oncol CrossRef
244. Targeted Therapies in Advanced Cholangiocarcinoma
     Michael H. Storandt et al, 2023, Life CrossRef
245. Technological advances define shifting pathway signaling from normal to primary and metastatic colorectal cancer
     Robert G. Ramsay et al, 2023, Growth Factors CrossRef
246. Regulation of Epithelial-Mesenchymal Transitions by Alternative Splicing: Potential New Area for Cancer Therapeutics
     Ling Li et al, 2023, Genes CrossRef
247. Virtual screening for novel FGFR2 inhibitors: Exploring Gefitinib-like compounds as promising therapeutic candidates
     Salimat O. Sofela et al, 2023, Informatics in Medicine Unlocked CrossRef
248. Environment relevant exposure of perfluorooctanoic acid accelerates the growth of hepatocellular carcinoma cells through mammalian target of rapamycin (mTOR) signal pathway
     Jiawei Hong et al, 2023, Environmental Pollution CrossRef
249. The Role of the Tumor Microenvironment in Triple-Positive Breast Cancer Progression and Therapeutic Resistance
     Qian Pu et al, 2023, Cancers CrossRef
250. Identification and validation of basic fibroblast growth factor as a prognostic biomarker for the response of lung adenocarcinoma patients to bevacizumab treatment
     Hongtao Jiang et al, 2023, Immunobiology CrossRef
251. Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
     Jiangjun Cao et al, 2023, MedComm CrossRef
252. Synthesis and Evaluation of Novel 99mTc-Labeled FGFR2-Targeting Peptides
     Jingjing Yao et al, 2024, Mol. Pharmaceutics CrossRef
253. Identification and characterization of CLEC11A and its derived immune signature in gastric cancer
     Qing Zheng et al, 2024, Front. Immunol. CrossRef
254. Lipopolysaccharide-Educated Cancer-Associated Fibroblasts Facilitate Malignant Progression of Ovarian Cancer Cells via the NF-kB/IL-6/JAK2 Signal Transduction
     Dongjie Wang et al, 2024, Mol Biotechnol CrossRef
255. Network pharmacology, molecular simulation, and binding free energy calculation-based investigation of Neosetophomone B revealed key targets for the treatment of cancer
     Abbas Khan et al, 2024, Front. Pharmacol. CrossRef
256. Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D
     Anna Piotrowska et al, 2024, IJMS CrossRef
257. LGALS3BP is a novel and potential biomarker in clear cell renal cell carcinoma
     Lei Li et al, 2024, Aging CrossRef
258. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
     Masuko Katoh et al, 2024, Nat Rev Clin Oncol CrossRef
259. Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies
     Firas Batrash et al, 2024, Cancers CrossRef
260. Inhibitory Effect of the Ethanolic Seed Extract of Trichosanthes kirilowii on Angiogenesis in Human Umbilical Vein Endothelial Cells
     Shin-Hyung Park et al, 2022, kjopp CrossRef
261. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma
     Gaetano Pezzicoli et al, 2024, Medicina CrossRef
262. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
     Erika Stucchi et al, 2024, Expert Opinion on Pharmacotherapy CrossRef
263. Calcium and Neural Stem Cell Proliferation
     Dafne Astrid Díaz-Piña et al, 2024, IJMS CrossRef
264. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
     Keming Lin et al, 2024, J Transl Med CrossRef
265. Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression
     Hong Tian et al, 2024, Front. Oncol. CrossRef